Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXAINASDAQ:IBRXNASDAQ:IMVTNASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXAIExscientia$4.84$4.97$3.80▼$6.49$632.93M0.83651,934 shsN/AIBRXImmunityBio$2.53-5.6%$2.63$1.83▼$7.63$2.23B0.335.57 million shs6.25 million shsIMVTImmunovant$14.46-0.7%$15.46$12.72▼$34.47$2.46B0.751.22 million shs754,314 shsMLTXMoonLake Immunotherapeutics$38.93+1.1%$38.43$31.42▼$58.26$2.49B1.31353,569 shs133,169 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXAIExscientia0.00%0.00%0.00%0.00%-2.22%IBRXImmunityBio-5.60%-10.92%-5.95%-26.02%-63.54%IMVTImmunovant-0.69%0.00%+0.07%-31.98%-51.08%MLTXMoonLake Immunotherapeutics+1.09%+3.48%-1.47%-7.92%-2.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXAIExscientiaN/AN/AN/AN/AN/AN/AN/AN/AIBRXImmunityBio1.8247 of 5 stars3.61.00.00.01.91.70.6IMVTImmunovant2.6995 of 5 stars4.51.00.00.03.61.70.0MLTXMoonLake Immunotherapeutics3.1441 of 5 stars4.52.00.00.03.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXAIExscientia 2.00Hold$5.003.31% UpsideIBRXImmunityBio 3.20Buy$12.25384.19% UpsideIMVTImmunovant 2.90Moderate Buy$38.33165.10% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$78.71102.19% UpsideCurrent Analyst Ratings BreakdownLatest EXAI, MLTX, IMVT, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025IBRXImmunityBioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$4.25 ➝ $5.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.005/12/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/12/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/5/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/28/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/23/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXAIExscientia$25.60M24.72N/AN/A$2.54 per share1.91IBRXImmunityBio$31.22M71.52N/AN/A($0.88) per share-2.88IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXAIExscientia-$181.56M-$1.51N/AN/AN/A-882.09%-49.10%-33.13%N/AIBRXImmunityBio-$583.20M-$0.58N/AN/AN/A-8,016.83%N/A-110.02%8/11/2025 (Estimated)IMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$2.30N/AN/AN/AN/A-15.54%-15.09%8/6/2025 (Estimated)Latest EXAI, MLTX, IMVT, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q4 2025IMVTImmunovant-$0.72N/AN/AN/AN/AN/A5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A3/3/2025Q4 2024IBRXImmunityBio-$0.26-$0.15+$0.11-$0.09$8.74 million$7.55 million2/26/2025Q4 2024MLTXMoonLake Immunotherapeutics-$0.63-$0.72-$0.09-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXAIExscientiaN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXAIExscientia0.064.544.54IBRXImmunityBioN/A2.682.64IMVTImmunovantN/A6.046.04MLTXMoonLake ImmunotherapeuticsN/A25.5125.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXAIExscientia41.58%IBRXImmunityBio8.58%IMVTImmunovant47.08%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipEXAIExscientia16.40%IBRXImmunityBio76.79%IMVTImmunovant5.90%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXAIExscientia280130.77 million109.32 millionOptionableIBRXImmunityBio590882.62 million115.67 millionOptionableIMVTImmunovant120169.86 million159.84 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableEXAI, MLTX, IMVT, and IBRX HeadlinesRecent News About These CompaniesNuveen Asset Management LLC Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 24 at 4:05 AM | marketbeat.comPoint72 Asset Management L.P. Invests $5.35 Million in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 22 at 4:42 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Wolfe Research to Outperform RatingMay 21 at 8:15 AM | marketbeat.comWexford Capital LP Purchases 10,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 21 at 7:06 AM | marketbeat.comAmeriprise Financial Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 21 at 3:27 AM | marketbeat.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX)May 20, 2025 | msn.comWolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform"May 20, 2025 | americanbankingnews.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) with a Bullish Outlook | MLTX Stock NewsMay 19, 2025 | gurufocus.comEnsign Peak Advisors Inc Sells 33,174 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 19, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 19, 2025 | marketbeat.comWedbush Issues Optimistic Outlook for MLTX EarningsMay 18, 2025 | americanbankingnews.comPolar Capital Holdings Plc Raises Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 17, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Moderate Buy" by AnalystsMay 17, 2025 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comParadigm Biocapital Advisors LP Purchases 840,731 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $2.94 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 16, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Lowered by Schonfeld Strategic Advisors LLCMay 16, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases Shares of 64,384 MoonLake Immunotherapeutics (NASDAQ:MLTX)May 16, 2025 | marketbeat.comWall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a BetMay 15, 2025 | zacks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from Needham & Company LLCMay 15, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Expectations By $0.13 EPSMay 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXAI, MLTX, IMVT, and IBRX Company DescriptionsExscientia NASDAQ:EXAIExscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.ImmunityBio NASDAQ:IBRX$2.53 -0.15 (-5.60%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.54 +0.01 (+0.40%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Immunovant NASDAQ:IMVT$14.46 -0.10 (-0.69%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$14.47 +0.01 (+0.07%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MoonLake Immunotherapeutics NASDAQ:MLTX$38.93 +0.42 (+1.09%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$38.98 +0.05 (+0.14%) As of 05/23/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
